On 19 December 2025, the TVB ESG Awards 2025 Presentation Ceremony, hosted by Television Broadcasts Limited (“TVB”), was held at the Hong Kong Convention and Exhibition Center. Fosun International was honored with the highest accolade, the “Outstanding ESG Award”, as well as awards for “Best in ESG Practices” and “Best in ESG Report”.

9 December 2025 -- Fosun Pharma (SSE: 600196; HKEX: 02196) today announced that its subsidiaries, Chongqing Yao Pharmaceutical Company, Limited. ("Yao Pharma"), Shanghai Fosun Pharmaceutical Industrial Development Company Limited, and Pfizer Inc. (NYSE: PFE) have entered into an exclusive collaboration and license agreement. Under this agreement, Yao Pharma grants Pfizer an exclusive worldwide license for the development, use, manufacturing, and commercialization of oral small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonists, including YP05002, and any products containing such oral small molecule GLP-1R agonists as an active ingredient. The license covers all indications for therapeutic, diagnostic, and prophylactic human and veterinary use. Under the terms of the agreement, Yao Pharma will complete an ongoing YP05002 Phase 1 clinical trial in Australia and grants Pfizer an exclusive license to further develop, manufacture and commercialize YP05002 worldwide.

Sanya, China, On 28 November 2025, Fosun Tourism Group hosted "Fosun Holiday Horizon 2026" at Atlantis Sanya, where it systematically unveiled its three core product lines for the first time and signed 18 partnership agreements with cultural tourism investment institutions and industry partners from various regions. These developments are set to inject new momentum into the high-quality growth of China's cultural tourism sector.

A devastating fire broke out at residential buildings in Wang Fuk Court, Tai Po, New Territories, Hong Kong, resulting in casualties. Fosun Foundation, together with Fosun International, ecosystem enterprises including Fosun Pharma, Forte Hong Kong, Henlius, Fosun Wealth, Peak Re, and Fosun Asset Management, as well as singer Zhou Shen, 北京時代立方文化傳播有限公司, girl group singer i-dle, and other caring individuals and organizations, has pledged a donation of HKD10 million to support emergency relief and recovery efforts.

Shanghai, China, November 20, 2025 — Shanghai Henlius Biotech, Inc. (2696.HK) announced that its self-developed innovative anti-PD-1 monoclonal antibody HANSIZHUANG (serplulimab, Hetronifly^®in Europe), in combination with chemotherapy for neo-/adjuvant treatment for gastric cancer, has been officially granted the Breakthrough Therapy Designation (BTD) by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). This marks the first gastric cancer perioperative drug to receive the CDE’s BTD. Previously, the phase 3 clinical trial of this therapy met its primary endpoints. As the world's first perioperative gastric cancer treatment regimen replacing chemotherapy with immunotherapy alone in the adjuvant setting, it demonstrates potential to deliver dual breakthroughs in survival benefits and quality of life for patients.

On 19 November, the 7th “ESG Leading Enterprises 2025” ceremony, co-organized by Bloomberg Businessweek/Chinese Edition and Deloitte, a globally renowned accounting firm, was successfully held in Hong Kong. The event was honored to feature a keynote speech and award presentation by Mr. Joseph H.L. Chan, JP, Under Secretary for Financial Services and the Treasury of the Government of Hong Kong Special Administrative Region. Fosun International was honored as an “ESG Leading Enterprise”, in recognition of its outstanding achievements and strong market position across ESG strategy, corporate governance, social responsibility, environmental protection, information disclosure, and stakeholder engagement.

On 18 November, the Chief Executive’s Policy Unit (CEPU) of the Government of the Hong Kong Special Administrative Region, the National Academy of Economic Strategy of the Chinese Academy of Social Sciences, and the Chinese Institute of Hong Kong held the Economic Transformations in a Multipolar World - International Forum on China’s Economy and Policy 2025 at the Central Government Offices. Guo Guangchang, Chairman of Fosun International, joined the session “The New Development Landscape of Hong Kong” and delivered a speech highlighting Hong Kong’s pivotal role in advancing economic globalization and regional integration. He further emphasized that innovation is the key to shaping a vibrant future for Hong Kong.

On 13 November 2025, Hong Kong Economic Journal (HKEJ), Hong Kong’s first Chinese-language financial newspaper, hosted the “ESG & Sustainability Awards of Excellence 2025” ceremony. At the event, Fosun International received the “ESG & Corporate Sustainability Excellence Award”, recognizing its remarkable achievements and strong market standing in advancing environmental, social, and governance (ESG) practices as well as sustainability.

SHANGHAI, China – NOVEMBER 11, 2025 – Shanghai Henlius Biotech, Inc. (2696.HK) today announced the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom has granted marketing authorization for BILDYOS^® (denosumab) injection 60 mg/mL and BILPREVDA^® (denosumab) injection 120 mg/1.7 mL, biosimilars to PROLIA (denosumab) and XGEVA (denosumab), respectively, for all indications of the reference products.